Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Method of treating lupus by administering an anti-IL-12 antibody
US9862766B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9862766-B2 |
| Application number | US-201715432636-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 14, 2017 |
| Priority date | Aug 7, 2000 |
| Publication date | Jan 9, 2018 |
| Grant date | Jan 9, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for reducing symptoms of lupus in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody, wherein said antibody binds to a conformational epitope of IL-12 protein comprising residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of SEQ ID NO:9, to said animal. 2. The method according to claim 1 , wherein the lupus is systemic lupus erythematosus. 3. The method according to claim 1 , wherein said effective amount is 0.001-50 mg/kilogram of said animal. 4. The method according to claim 1 , wherein said administering is by at least one mode selected from subcutaneous and intravenous. 5. The method according to claim 1 , further comprising administering an effective amount of a cytokine antagonist. 6. A method for reducing symptoms of lupus in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody, wherein said antibody binds to a conformational epitope of IL-12 protein comprising residues 23, 40, 43, 45, 59, and 62 of the amino acid sequence of SEQ ID NO:9, to said animal. 7. The method according to claim 6 , wherein the lupus is systemic lupus erythematosus. 8. The method according to claim 6 , wherein said effective amount is 0.001-50 mg/kilogram of said animal. 9. The method according to claim 6 , wherein said administering is by at least one mode selected from subcutaneous and intravenous. 10. The method according to claim 6 , further comprising administering an effective amount of a cytokine antagonist.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9862766B2 cover?
- An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, an…
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/244. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).